Publications

Year of Publication Title Faculty Association
2014 Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.
2014 The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth.
2013 Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities. Victor Hruby, Ph.D., Josephine Lai , Ph.D., Tally Largent-Milnes, PhD, Edita Navratilova, Frank Porreca, PhD, Todd Vanderah, PhD
2013 Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. Peg Davis, Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2013 Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments. Roberta Diaz Brinton, Ph.D
2013 Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2013 Effect of anchoring 4-anilidopiperidines to opioid peptides. Victor Hruby, Ph.D., Josephine Lai , Ph.D., Frank Porreca, PhD, Todd Vanderah, PhD
2013 Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. Patrick W Mantyh, Tally Largent-Milnes, PhD, Frank Porreca, PhD, Todd Vanderah, PhD
2013 Development of functionally selective, small molecule agonists at kappa opioid receptors. John M. Streicher, PhD
2013 Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Victor Hruby, Ph.D., Todd Vanderah, PhD
2013 Cancer-induced bone pain: Mechanisms and models. Todd Vanderah, PhD
2013 Estrogen, astrocytes and the neuroendocrine control of metabolism. Roberta Diaz Brinton, Ph.D
2013 Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of Akt/JNK signaling and PGC1α transcriptional pathway. Roberta Diaz Brinton, Ph.D
2013 Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. John M. Streicher, PhD
2013 Neurosteroids as regenerative agents in the brain: therapeutic implications. Roberta Diaz Brinton, Ph.D
2013 Maintenance of mitochondrial genomic integrity in the absence of manganese superoxide dismutase in mouse liver hepatocytes.
2013 Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. Roberta Diaz Brinton, Ph.D
2013 Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. Roberta Diaz Brinton, Ph.D
2013 Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. Roberta Diaz Brinton, Ph.D
2012 17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain. Roberta Diaz Brinton, Ph.D
2012 Intranasal delivery of biologics to the central nervous system. Jeffrey J. Lochhead, PhD
2012 Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. John M. Streicher, PhD
2012 Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. Tally Largent-Milnes, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2012 Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation. Victor Hruby, Ph.D., Tally Largent-Milnes, PhD, Todd Vanderah, PhD, Eva Varga, Ph.D.
2012 Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Frank Porreca, PhD, Todd Vanderah, PhD

Pages